{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:48:19Z","timestamp":1792118899627,"version":"4.4.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"\n Importance<\/jats:title>\n Essential tremor (ET) is the most common form of arm tremor. Transcutaneous peripheral nerve stimulation (TPNS) can modulate the central tremor-generating network.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate whether an artificial intelligence (AI)\u2013driven TPNS device is superior to a sham device in reducing ET.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A randomized clinical trial was conducted from February 7 through August 9, 2024, in 12 outpatient neurology clinics in the United States and China. Participants were adults with upper-extremity tremor and a clinical diagnosis of ET, a tremor severity score of 2 or higher on 1 of the Essential Tremor Rating Assessment Scale (TETRAS) performance subscale tasks, a total performance subscale score of at least 7, and familiarity with operating a smartphone and connecting to Wi-Fi at home. They were randomized 2:1 to receive active TPNS or sham stimulation, stratified by use of ET medications and tremor severity. After the devices were fitted, the participants were instructed to use them during waking hours for 90 days.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n A wearable neuromodulation device that stimulates the radial, median, and ulnar nerves and uses AI to continuously adjust stimulation settings in real time.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome was change in daily activities as measured by the modified Activities of Daily Living (mADL) subscale of TETRAS at 90 days in the intention-to-treat population.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 133 screened, 125 were randomized to receive TPNS (n\u2009=\u200983) or sham (n\u2009=\u200942) treatment. The mean (SD) age was 64.9 (13.1) years, 62 (49.6%) were female and 63 (50.4%) male, and the mean (SD) tremor duration was 11.4 (13.1) years. At 90 days, the mADL score was reduced by 6.9 points (95% CI, 5.4-8.4) in the TPNS group vs 2.7 points (95% CI, 1.3-4.0) in the sham group (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Skin irritation, the most common device-related adverse event, occurred in 28 of 83 participants (33.7%) in the TPNS group and 2 of 42 (4.8%) in the sham group. Nausea, arthralgia, worsening of existing arthritis in the thumb, muscular weakness, and involuntary muscle contractions each occurred in 1 participant, all in the TPNS group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The TPNS device improved activities related to upper limb tremor at 90 days and could be an effective noninvasive ET treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06235190<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.3905","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:31:07Z","timestamp":1760974267000},"page":"1235","source":"Crossref","is-referenced-by-count":9,"title":["Transcutaneous Peripheral Nerve Stimulation for Essential Tremor"],"prefix":"10.1001","volume":"82","author":[{"given":"William G.","family":"Ondo","sequence":"first","affiliation":[{"name":"Houston Methodist Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Lv","sequence":"additional","affiliation":[{"name":"Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Hu","sequence":"additional","affiliation":[{"name":"Xuanwu Hospital Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorder Center of Boca Raton, Boca Raton, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[{"name":"University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kreitzman","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Research Centers of America \u2013 Long Island, Long Island, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Han","family":"Kuo","sequence":"additional","affiliation":[{"name":"Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salima","family":"Brillman","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Research Centers of America \u2013 Palo Alto, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly A.","family":"Shill","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute, Phoenix, Arizonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Lyons","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Fasikl Inc, Bloomington, Minnesota"},{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Fasikl Inc, Bloomington, Minnesota"},{"name":"University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fasikl Inc, Bloomington, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"noi250071r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106086","article-title":"Updates in essential tremor.","volume":"122","author":"Okelberry","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"noi250071r2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5334\/tohm.632","article-title":"How common is essential tremor? update on the worldwide prevalence of essential tremor.","volume":"11","author":"Louis","year":"2021","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"19","key":"noi250071r3","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1212\/WNL.0b013e318236f0fd","article-title":"Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.","volume":"77","author":"Zesiewicz","year":"2011","journal-title":"Neurology"},{"issue":"12","key":"noi250071r4","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1212\/WNL.39.12.1587","article-title":"Acute and chronic effects of propranolol and primidone in essential tremor.","volume":"39","author":"Koller","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"noi250071r5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1212\/WNL.36.1.121","article-title":"Efficacy of primidone in essential tremor.","volume":"36","author":"Koller","year":"1986","journal-title":"Neurology"},{"key":"noi250071r6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5334\/tohm.198","article-title":"How many people in the USA have essential tremor? deriving a population estimate based on epidemiological data.","volume":"4","author":"Louis","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"9255","key":"noi250071r7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(00)04044-7","article-title":"Tremor-correlated cortical activity in essential tremor.","volume":"357","author":"Hellwig","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"noi250071r8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/jnnp.64.2.273","article-title":"Thalamic neuronal activity correlated with essential tremor.","volume":"64","author":"Hua","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi250071r9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5334\/tohm.59","article-title":"Prospective home-use study on non-invasive neuromodulation therapy for essential tremor.","volume":"10","author":"Isaacson","year":"2020","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"noi250071r10","doi-asserted-by":"publisher","first-page":"462","DOI":"10.5334\/tohm.378","article-title":"Focused ultrasound for essential tremor: review of the evidence and discussion of current hurdles.","volume":"7","author":"Rohani","year":"2017","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"4","key":"noi250071r11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1017\/cjn.2016.35","article-title":"Eligibility criteria for deep brain stimulation in Parkinson\u2019s disease, tremor, and dystonia.","volume":"43","author":"Munhoz","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"noi250071r12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12984-021-00811-9","article-title":"Peripheral electrical stimulation to reduce pathological tremor: a review.","volume":"18","author":"Pascual-Valdunciel","year":"2021","journal-title":"J Neuroeng Rehabil"},{"issue":"Pt 8","key":"noi250071r13","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/brain\/123.8.1545","article-title":"Physiological and pathological tremors and rhythmic central motor control.","volume":"123","author":"McAuley","year":"2000","journal-title":"Brain"},{"key":"noi250071r14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5334\/tohm.685","article-title":"Rationale and evidence for peripheral nerve stimulation for treating essential tremor.","volume":"12","author":"Wagle Shukla","year":"2022","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"5","key":"noi250071r16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/ner.12930","article-title":"An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor.","volume":"22","author":"Pahwa","year":"2019","journal-title":"Neuromodulation"},{"issue":"12","key":"noi250071r17","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/mds.25162","article-title":"Reliability of a new scale for essential tremor.","volume":"27","author":"Elble","year":"2012","journal-title":"Mov Disord"},{"issue":"4","key":"noi250071r18","doi-asserted-by":"publisher","DOI":"10.29245\/2572.942X\/2016\/4.1038","article-title":"The Essential Tremor Rating Assessment Scale.","volume":"1","author":"Elble","year":"2016","journal-title":"J Neurol Neuromedicine"},{"issue":"6","key":"noi250071r19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.parkreldis.2005.05.009","article-title":"Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation.","volume":"11","author":"Tr\u00f6ster","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"noi250071r20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/mds.27660","article-title":"Minimal clinically important difference for the quality of life in essential tremor questionnaire.","volume":"34","author":"Pint\u00e9r","year":"2019","journal-title":"Mov Disord"},{"key":"noi250071r21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5334\/tohm.991","article-title":"A pilot study of AI-controlled transcutaneous peripheral nerve stimulation for essential tremor.","volume":"15","author":"Dewey","year":"2025","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"noi250071r15","unstructured":"US Food and Drug Administration. Cala kIQ 510(k) Premarket Notification (2024). Accessed January 7, 2025. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/pmn.cfm?ID=K242259"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2840156\/jamaneurology_ondo_2025_oi_250071_1764183369.52312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:01:04Z","timestamp":1765209664000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2840156"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.3905","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}